#Akero Therapeutics (AKRO) - Prohost Biotech

Akero Therapeutics Announced It Entered into a Definitive Agreement to be Acquired by Novo Nordisk

Akero Therapeutics Acquisition Agreement Today, October 9, 2025, Akero Therapeutics ( AKRO ) announced that it entered into a definitive agreement to be acquired by Novo Nordisk ( NVS ) A/S for up to...

P

Prohost Biotech

Oct 9, 2025

Akero Therapeutics Q2 Financial and Study Results

Akero Therapeutics Akero Therapeutics ( AKRO ) reported its Q22025 financial results for the period ending June 30, 2025 as well as providing a business update. The report was published from the 96-We...

P

Prohost Biotech

Aug 11, 2025

Why Many Biotech Investors Believe Akero Therapeutics Will Soon Be Acquired By A Top-Tier Company

Akero Therapeutics Akero Therapeutics ( AKRO ) - a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, includi...

P

Prohost Biotech

May 23, 2025

Complete Preliminary Week 96 Results from Akero Therapeutics EFX Results

Akero Therapeutics Full Press Release Following our shortened report earlier today, this posting is from the Company’s information and its press release. The news demonstrated statistically significan...

P

Prohost Biotech

Jan 27, 2025

Akero Therapeutics Successful Results

Akero Therapeutics Waiting to hear the news from Akero Therapeutics in treating NASH, the company reported Preliminary Topline Results showing statistically significant reversal of compensated Cirrhos...

P

Prohost Biotech

Jan 27, 2025

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ ( GILD ) stock price has been paralyzed for more than three consecutive years. T...

P

Prohost Biotech

Aug 21, 2024

Akero Therapeutics Reports Q2 2024 Financial Results and Business Update

Akero Therapeutics Q2 and Business Update Akero Therapeutics ( AKRO ) reported second-quarter financial results for the period ending June 30, 2024, and provided business updates. From Akero Therapeu...

P

Prohost Biotech

Aug 9, 2024

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

From Akero Therapeutics Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero Therapeutics remarked, "I am delighted to welcome Scott Gangloff to Akero. His depth of experience le...

P

Prohost Biotech

Apr 30, 2024

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Akero Therapeutics Akero Therapeutics ( AKRO ) released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin...

P

Prohost Biotech

Mar 4, 2024

Prohost Letter #459 ~ NAFLD & NASH

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is Non-Alcoholic Steatohepatitis. We will start with NAFLD. NAFLD The Non-Alcoholic Fatty Liver Disease is cau...

P

Prohost Biotech

Mar 3, 2024

Current News From Three Selected Biotech Firms

Three Biotech Firm in the NEWS Verona Pharma Verona Pharma plc ( VRNA ) announced that senior management will present a company overview at the following conferences in November 2023: Jefferies London...

P

Prohost Biotech

Nov 8, 2023

Akero Therapeutics' October 10, 2023 Press Release

Akero Therapeutics Press Release Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results...

P

Prohost Biotech

Oct 10, 2023

Please Don't Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH Investor webcast on Tuesday, October 10th at 8:00 a.m....

P

Prohost Biotech

Oct 9, 2023

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

Akero Therapeutics Akero Therapeutics ( AKRO ) announced publication in The Lancet Gastroenterology & Hepatology of results from the HARMONY Phase 2b trial in nonalcoholic steatohepatitis ( NASH ). Th...

P

Prohost Biotech

Oct 4, 2023

Promising Stocks in the First Two Trading Days of 2023

The Stock Market in the New Year It is still too early to tell how the stock market will perform in 2023. However, o n Tuesday January 3, 2023 (the first market trading day in 2023), most biotech stoc...

P

Prohost Biotech

Jan 4, 2023

Gilead Sciences - Still Way Undervalued

Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead Science’s ( GILD ) stock for years are upgrading it. Demonstrating time and time again...

P

Prohost Biotech

Dec 29, 2022

A Note To Our Followers

Dear Friends and Followers, We confirm our optimism towards the future biotech firms that we selected for investment, including the clinical stage small biotech companies, which also includes biotech...

P

Prohost Biotech

Dec 23, 2022

Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved

Treatments for NASH Madrigal Pharmaceuticals ( MDGL ) is the second company after Akero Therapeutics ( AKRO ) to announce positive top-line late results for Nonalcoholic steatohepatitis (NASH). Its pr...

P

Prohost Biotech

Dec 19, 2022

Acumen Pharmaceuticals: New Effort to Treat Alzheimer’s Disease Granted FDA Fast Track Designation

Acumen Pharmaceuticals Product ACU193 On October 23, 2022, Acumen Pharmaceuticals ( ABOS ) announced that the first clinical-stage monoclonal antibody ACU193 - an anti-amyloid beta oligomer antibody,...

P

Prohost Biotech

Oct 25, 2022

Treating Untreatable Disease - NASH

Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis The efforts spent on treating Non Alcoholic Steatohepatitis (NASH) have reached a promising stage where clinical...

P

Prohost Biotech

Oct 13, 2022

1m

32